- Who we areWho we are
We are a biotechnology company committed to helping address serious infectious diseases globally through the discovery and development of innovative vaccines to patients around the world.
Build your future with usJoin other passionately curious people who are bringing innovative vaccines to the world
- What we doWhat we do
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
COVID-19 UPDATESNovavax has demonstrated its ability to quickly develop viable vaccine candidates for emerging infectious diseases such as COVID-19.
- Blog
Novavax to Showcase Innovative Vaccine Data at Communicable Diseases & Immunisation Conference 2022
Novavax will present encore safety and immunogenicity data from its COVID-19 vaccine (NVX-CoV2373) trials, as well as encore safety and efficacy data on the Novavax Influenza vaccine candidate at the Communicable Diseases & Immunisation Conference (CDIC) 2022 in Sydney, Australia, from June 20 to 22, 2022. Data will be presented during six oral presentations at the conference.
Novavax presentations during CDIC:
Toback, S | Ongoing Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine in the United Kingdom | Oral (encore) Monday, June 20, 2022 1:30 PM - 3:00 PM AEST |
Shinde, V | Phase 3 trial of a SARS-CoV-2 Protein Vaccine (NVX-CoV2373) in Adolescents (PREVENT-19) | Oral (encore) Monday, June 20, 2022 1:30 PM - 3:00 PM AEST |
Beyhaghi, H | Reported Pregnancies and Associated Outcomes Across the Novavax COVID-19 Vaccine Clinical Program | Oral (encore) Monday, June 20, 2022 3:30 PM - 5:00 PM AEST |
Marchese, A | COVID-19 Vaccine Receptivity and Preferences among Vaccine Hesitant Individuals | Oral (encore) Monday, June 20, 2022 3:30 PM - 5:00 PM AEST |
Toback, S | The Safety and Efficacy of NVX-CoV2373 Co-administered With Seasonal Influenza Vaccine | Oral (encore) Tuesday, June 21, 2022 1:30 PM - 3:00 PM AEST |
Shinde, V | Long-term polyfunctional CD4+ T-cell responses after recombinant hemagglutinin saponin-adjuvanted nanoparticle influenza vaccination | Oral (encore) Tuesday, June 21, 2022 1:30 PM - 3:00 PM AEST |
